KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Free Cash Flow readings, the most recent being -$47.7 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 15.07% to -$47.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$178.7 million, a 53.23% increase, with the full-year FY2025 number at -$178.7 million, up 53.23% from a year prior.
  • Free Cash Flow hit -$47.7 million in Q4 2025 for Ginkgo Bioworks Holdings, down from -$31.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$10.7 million in Q3 2021 to a low of -$170.7 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$65.7 million (2021), compared with a mean of -$75.6 million.
  • Biggest five-year swings in Free Cash Flow: crashed 368.63% in 2023 and later soared 73.35% in 2025.
  • Ginkgo Bioworks Holdings' Free Cash Flow stood at -$170.7 million in 2021, then rose by 23.72% to -$130.2 million in 2022, then surged by 52.93% to -$61.3 million in 2023, then rose by 8.38% to -$56.1 million in 2024, then increased by 15.07% to -$47.7 million in 2025.
  • The last three reported values for Free Cash Flow were -$47.7 million (Q4 2025), -$31.6 million (Q3 2025), and -$40.3 million (Q2 2025) per Business Quant data.